Biolegend, 317428, PerCP/Cyanine5.5 anti-human CD4 Antibody, 100tests

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.
100tests
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: Chimpanzee
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human peripheral T cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
Excitation Laser: Blue Laser (488 nm)
Application Notes: The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36. Linder J, et al. 1987. Am. J. Pathol. 127:1. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC) Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen) Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations: Charpentier JC, et al. 2020. Nat Commun. 11:180. PubMed Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed Xie Q, et al. 2023. iScience. 26:106395. PubMed Pfister F, et al. 2023. Methods Mol Biol. 2644:331. PubMed Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed Wu Y, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed Chan JA, et al. 2022. Nat Commun. 13:4159. PubMed Ellis GI, et al. 2022. Cell Rep Med. 3:100614. PubMed Graciliano NG, et al. 2023. Front Immunol. 13:1031248. PubMed Edwards CL, et al. 2023. J Clin Invest. 133: . PubMed Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed Kongsbak M, et al. 2014. PLoS One. 9:96695. PubMed Chiu YL, et al. 2018. Immun Ageing. 15:27. PubMed Shoda H, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1308-y. PubMed Weymar GHJ, et al. 2022. Cell Rep. 40:111311. PubMed Nagafuchi Y, et al. 2016. Sci Rep. 6:29338. PubMed Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed Weber MG, et al. 2021. JCI Insight. 6:. PubMed Hasaart KAL, et al. 2020. Sci Rep. 10:12991. PubMed Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed Grenga I, et al. 2016. Clin Transl Immunology. 0.265972222. PubMed Lopatina T, et al. 2018. Sci Rep. 8:17458. PubMed Goel G, et al. 2019. Sci Adv. 5:eaaw7756. PubMed Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed Buchan SL et al. 2018. Immunity. 49(5):958-970 . PubMed Wang N, et al. 2021. iScience. 24:103205. PubMed Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed Yamada E, et al. 2021. Gut Microbes. 13:1997292. PubMed Heery C, et al. 2015. Cancer Immunol Res. 3: 1248 - 1256. PubMed Neff CP et al. 2018. EBioMedicine. 30:192-202 . PubMed Zhang P, et al. 2022. BMC Med. 20:435. PubMed Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed Imai Y, et al. 2021. JID Innov. 1:100003. PubMed Ye C, et al. 2017. J Virol. 91:e01389-23. PubMed Wu D, et al. 2020. Biomark Res. 8:3. PubMed Gullà A, et al. 2021. Cancer Discov. . PubMed Grivas A, et al. 2022. Front Immunol. 13:964274. PubMed Bego M, et al. 2015. J Vis Exp. 103: 51207. PubMed Harper JL, et al. 2020. Nat Med. 519:26. PubMed Song TZ, et al. 2021. Front Endocrinol (Lausanne). 12:745984. PubMed Zhang XL, et al. 2020. J Virol. 94:. PubMed Newton HS, et al. 2021. Mol Ther Methods Clin Dev. 21:133. PubMed Su S et al. 2018. Cell. 175(2):442-457 . PubMed Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed Shi Y, et al. 2014. Proc Natl Acad Sci U S A. 111:3092.. PubMed Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed Grigoriou M, et al. 2021. Cancer Immunol Res. 9:726. PubMed Chheda ZS, et al. 2018. J Exp Med. 9:19490. PubMed Pham TNQ, et al. 2020. Cell Reports. 29(9):2770-2782.e5.. PubMed Crompton J, et al. 2015. Cancer Res. 75:296. PubMed Florek N, et al. 2014. J Virol. 88:13418. PubMed Ferraro A, et al. 2014. Proc Natl Acad Sci U S A. 111:1111. PubMed Liu H, et al. 2021. Virology. 560:76. PubMed Meira M, et al. 2014. Mult Scler. 20:1363. PubMed Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed Gullà A, et al. 2021. Cancer Discov. 2:468. PubMed Winkler C, et al. 2021. JCI Insight. 6:. PubMed Ishigaki K, et al. 2015. Sci Rep. 5: 12937. PubMed Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed Jin J, et al. 2014. PLoS One. 9:104753. PubMed Ma G, et al. 2015. Proc Natl Acad Sci U S A. 112:2216. PubMed Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed Aguilar–Briseñ o JA, et al. 2020. Nat Commun. 2.664583333. PubMed Mann EH, et al. 2019. J Immunol. 202:684. PubMed
RRID: AB_1186124 (BioLegend Cat. No. 317427) AB_1186122 (BioLegend Cat. No. 317428)
Structure: Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution: T cell subset, majority of thymocytes, monocytes/macrophages
Function: MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor: MHC class II molecules, HIV gp120, IL-16
Cell Type: Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Center D, et al. 1996. Immunol. Today 17:476. 2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.
Gene ID: 920
UniProt: View information about CD4 on UniProt.org
Clone: OKT4
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T4
Isotype: Mouse IgG2b, κ
Q: I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
A: TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Q: How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?
A: PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.